| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Therapy: Clinical |
Authors' Affiliations: 1 Department of Medicine, Division of Hematology/Oncology; 2 Department of Biomathematics; Departments of 3 Pathology and Laboratory Medicine and 4 Medicine, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at University of California at Los Angeles; 5 Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, California; 6 Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee; 7 Pharmaceutical Development Center, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; and 8 OSI Pharmaceuticals, Inc., Boulder, Colorado
Requests for reprints: Karen L. Reckamp, David Geffen School of Medicine at University of California at Los Angeles, 10945 LeConte Avenue, Suite 2333, Los Angeles, CA 90095. Phone: 310-825-5788; Fax: 310-267-1491; E-mail: kreckamp{at}mednet.ucla.edu.
Purpose: Overexpression of cyclooxygenase-2 (COX-2) activates extracellular signal-regulated kinase/mitogen-activated protein kinase signaling in an epidermal growth factor receptor (EGFR) tyrosine kinase inhibition (TKI)–resistant manner. Because preclinical data indicated that tumor COX-2 expression caused resistance to EGFR TKI, a phase I trial to establish the optimal biological dose (OBD), defined as the maximal decrease in urinary prostaglandin E-M (PGE-M), and toxicity profile of the combination of celecoxib and erlotinib in advanced non–small cell lung cancer was done.
Experimental Design: Twenty-two subjects with stage IIIB and/or IV non–small cell lung cancer received increasing doses of celecoxib from 200 to 800 mg twice daily (bid) and a fixed dose of erlotinib. Primary end points included evaluation of toxicity and determination of the OBD of celecoxib when combined with erlotinib. Secondary end points investigate exploratory biological markers and clinical response.
Results: Twenty-two subjects were enrolled, and 21 were evaluable for the determination of the OBD, toxicity, and response. Rash and skin-related effects were the most commonly reported toxicities and occurred in 86%. There were no dose-limiting toxicities and no cardiovascular toxicities related to study treatment. All subjects were evaluated on intent to treat. Seven patients showed partial responses (33%), and five patients developed stable disease (24%). Responses were seen in patients both with and without EGFR-activating mutations. A significant decline in urinary PGE-M was shown after 8 weeks of treatment, with an OBD of celecoxib of 600 mg bid.
Conclusions: This study defines the OBD of celecoxib when combined with a fixed dose of EGFR TKI. These results show objective responses with an acceptable toxicity profile. Future trials using COX-2 inhibition strategies should use the OBD of celecoxib at 600 mg bid.
This article has been cited by other articles:
|
|
 |
|
  K.-Y. Chang, M.-R. Shen, M.-Y. Lee, W.-L. Wang, W.-C. Su, W.-C. Chang, and B.-K. Chen Epidermal Growth Factor-activated Aryl Hydrocarbon Receptor Nuclear Translocator/HIF-1{beta} Signal Pathway Up-regulates Cyclooxygenase-2 Gene Expression Associated with Squamous Cell Carcinoma J. Biol. Chem., April 10, 2009; 284(15): 9908 - 9916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Mutter, B. Lu, D. P. Carbone, I. Csiki, L. Moretti, D. H. Johnson, J. D. Morrow, A. B. Sandler, Y. Shyr, F. Ye, et al. A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non-Small Cell Lung Cancer Clin. Cancer Res., March 15, 2009; 15(6): 2158 - 2165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Van Dyke, M. L. Cote, G. M. Prysak, G. B. Claeys, A. S. Wenzlaff, V. C. Murphy, F. Lonardo, and A. G. Schwartz COX-2/EGFR expression and survival among women with adenocarcinoma of the lung Carcinogenesis, September 1, 2008; 29(9): 1781 - 1787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Huang, R. Eisenberg, M. Yan, S. Monti, E. Lawrence, P. Fu, J. Walbroehl, E. Lowenberg, T. Golub, J. Merchan, et al. 15-Hydroxyprostaglandin Dehydrogenase is a Target of Hepatocyte Nuclear Factor 3{beta} and a Tumor Suppressor in Lung Cancer Cancer Res., July 1, 2008; 68(13): 5040 - 5048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-C. Wang, S. K. Kulp, D. Wang, C.-C. Yang, A. M. Sargeant, J.-H. Hung, Y. Kashida, M. Yamaguchi, G.-D. Chang, and C.-S. Chen Targeting Endoplasmic Reticulum Stress and Akt with OSU-03012 and Gefitinib or Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Inhibitors Cancer Res., April 15, 2008; 68(8): 2820 - 2830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Fidler, A. Argiris, J. D. Patel, D. H. Johnson, A. Sandler, V. M. Villaflor, J. Coon IV, L. Buckingham, K. Kaiser, S. Basu, et al. The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non-Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib Clin. Cancer Res., April 1, 2008; 14(7): 2088 - 2094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kesari, D. Schiff, J. W. Henson, A. Muzikansky, D. C. Gigas, L. Doherty, T. T. Batchelor, J. A. Longtine, K. L. Ligon, S. Weaver, et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults Neuro-oncol, January 1, 2008; 10(3): 300 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Liu, S.-C. Yang, S. Sharma, J. Luo, X. Cui, K. A. Peebles, M. Huang, M. Sato, R. D. Ramirez, J. W. Shay, et al. EGFR Signaling Is Required for TGF-beta1 Mediated COX-2 Induction in Human Bronchial Epithelial Cells Am. J. Respir. Cell Mol. Biol., November 1, 2007; 37(5): 578 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G. Buchanan, V. Holla, S. Katkuri, P. Matta, and R. N. DuBois Targeting Cyclooxygenase-2 and the Epidermal Growth Factor Receptor for the Prevention and Treatment of Intestinal Cancer Cancer Res., October 1, 2007; 67(19): 9380 - 9388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. O'Byrne, S. Danson, D. Dunlop, N. Botwood, F. Taguchi, D. Carbone, and M. Ranson Combination Therapy With Gefitinib and Rofecoxib in Patients With Platinum-Pretreated Relapsed Non Small-Cell Lung Cancer J. Clin. Oncol., August 1, 2007; 25(22): 3266 - 3273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Buck, A. Eyzaguirre, S. Barr, S. Thompson, R. Sennello, D. Young, K. K. Iwata, N. W. Gibson, P. Cagnoni, and J. D. Haley Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition Mol. Cancer Ther., February 1, 2007; 6(2): 532 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Javle, S. Cao, F. A. Durrani, L. Pendyala, D. D. Lawrence, P. F. Smith, P. J. Creaven, D. C. Noel, R. V. Iyer, and Y. M. Rustum Celecoxib and Mucosal Protection: Translation from an Animal Model to a Phase I Clinical Trial of Celecoxib, Irinotecan, and 5-Fluorouracil Clin. Cancer Res., February 1, 2007; 13(3): 965 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ponthan, M. Wickstrom, H. Gleissman, O. M. Fuskevag, L. Segerstrom, B. Sveinbjornsson, C. P.F. Redfern, S. Eksborg, P. Kogner, and J. I. Johnsen Celecoxib Prevents Neuroblastoma Tumor Development and Potentiates the Effect of Chemotherapeutic Drugs In vitro and In vivo Clin. Cancer Res., February 1, 2007; 13(3): 1036 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Csiki and D. H. Johnson Did Targeted Therapy Fail Cyclooxygenase Too? J. Clin. Oncol., October 20, 2006; 24(30): 4798 - 4800. [Full Text] [PDF]
|
|
|
|
|
|
R. Lilenbaum, M. A. Socinski, N. K. Altorki, L. L. Hart, R. S. Keresztes, S. Hariharan, M. E. Morrison, R. Fayyad, and P. Bonomi Randomized Phase II Trial of Docetaxel/Irinotecan and Gemcitabine/Irinotecan With or Without Celecoxib in the Second-Line Treatment of Non-Small-Cell Lung Cancer J. Clin. Oncol., October 20, 2006; 24(30): 4825 - 4832. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
